Peraso released FY2025 Q2 earnings on August 13 After-Market EST, actual revenue USD 2.22 M (forecast USD 3.051 M), actual EPS USD -0.306 (forecast USD -0.76)

Brief Summary

Peraso’s Q2 2025 financial report showed revenue of 2.22 million USD, falling short of the expected 3.05 million USD, with an EPS of -0.306 USD, which exceeded the expected EPS of -0.76 USD.

Impact of The News

Impact Analysis:

1. Market Expectation:

• Peraso’s revenue missed the market expectation by approximately 0.83 million USD, indicating a weak revenue performance. However, the EPS was better than expected, showing a smaller loss than anticipated.

2. Comparison with Industry Peers:

• The company reported a negative EPS, which suggests challenges in attaining profitability. Compared to industry peers such as 和黄医药 (Hutchison China MediTech), which experienced declining revenue yet significant profit due to one-time gains, Peraso’s situation seems to be distinctly unfavorable for potential investors Zhitong+ 3.

3. Business Status:

• The revenue miss may imply underlying challenges in market penetration or competitive positioning. The improvement in EPS might suggest effective cost management or reduced expenditure compared to previous expectations.

4. Future Business Development Trends:

• Given the revenue shortfall, Peraso may need to reassess its business strategies, focusing on market expansion or product diversification to enhance revenue. The market may remain cautious about Peraso’s ability to generate consistent profits unless there is substantial strategic change or improvement in sales performance.